Genentech-Lodo sign agreement for soil-based drug discovery
Category: #health  By Paroma Bhattacharya  Date: 2018-05-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech-Lodo sign agreement for soil-based drug discovery

Genentech, a Roche subsidiary, has reportedly signed a deal with Lodo Therapeutics for around $1 billion to employ the genome mining technology of Lodo for a new drug discovery. The deal seems to be a first for Lodo which has a backing of $17 million from Accelerator Life Science Partners.

If reports are to be believed, the alliance includes an upfront amount that has not been disclosed and commercial and research and development milestone payments of $969 million. In the event that the products reach the market, tiered royalties would be provided on sales, as per a clause included in the deal. The disease categories that will be pursued through the alliance have not yet been disclosed.

Sources state that natural products have been the starting point for various drugs – similar to how microorganisms and plants have been the origins of various drugs like aspirin, derived from willow bark. As per estimates, in the last few decades, around three quarters of cancer drugs and medicines to treat chronic diseases like type 2 diabetes have been derived from natural sources. Authentic reports suggest that the increased focus of pharmaceutical companies on large-molecule drugs and synthetic small-molecules drugs based on combinatorial chemistry has slowed down the investment in naturally sourced drugs. However, this collaboration seemingly points toward the renewal of interest in naturally sourced medicines.

In partnership with Genentech, Lodo will search for naturally-occurring small molecules from microbial DNA that exhibit therapeutic potential. The process of drug discovery can be slow and depends largely on chance. Lodo Therapeutics claims to be able to speed up the process with its genome-based approach that also helps in lowering the costs of finding compounds for drug resistant bacterial infections and cancer.

Reliable sources quoted co-founder of Lodo Therapeutics, David Pompliano, saying that the strategic collaboration of Lodo Therapeutics with one of the leaders of innovative drug technology clearly highlights the potential of the proprietary platform that Lodo represents and its value to advanced drug discovery initiatives.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Outlook Therapeutics finishes patient registration for NORSE 1 trial
Outlook Therapeutics finishes patient registration for NORSE 1 trial
By Paroma Bhattacharya

  • NORSE 1 has registered a sum of 61 patients from nine different sites in Australia.
     
  • This study is first of the two current, well cont...

Lidl orders suppliers to pay duties on goods crossing Brexit borders
Lidl orders suppliers to pay duties on goods crossing Brexit borders
By Paroma Bhattacharya

  • The company has asked the British suppliers to pay any import tariffs levied on goods crossing borders after Brexit.
  • The current company contract c...

Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
By Paroma Bhattacharya

Bio-Thera Solutions, a China based pharmaceutical company, has reportedly announced the start of dosing of its first batch of healthy volunteers in order to compare the safety and pharmacokinetics of BAT2506, proposed ...